Quest Diagnostics (DGX) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenues reached $2.40 billion, up 2.5% year-over-year, with base business revenue growth of nearly 4%, driven by new customer wins, favorable test mix, and strong healthcare utilization.

• Announced and completed multiple acquisitions, including LifeLabs, PathAI Diagnostics, Lenco Diagnostic Laboratories, Allina Health, and OhioHealth, expanding geographic reach and advanced diagnostics capabilities.

• Productivity and profitability improved through automation, AI, and the Invigorate program, offsetting inflationary pressures.

• Net income attributable to Quest Diagnostics was $229 million for Q2 2024, down 2.4% year-over-year; adjusted diluted EPS was $2.35, up 2.2%.

• Ongoing cost-saving initiatives and operational improvements support future expansion amid regulatory and market headwinds.

Financial highlights

• Q2 consolidated revenues were $2.4 billion, up 2.5% year-over-year; base business revenues grew up to 4.2%.

• Adjusted operating income was $398 million (16.6% margin), up from $389 million; operating income was $355 million.

• Adjusted EPS was $2.35, up from $2.30; reported EPS was $2.03, down from $2.05 year-over-year.

• Cash from operations in Q2 was $360 million, down from $444 million last year; year-to-date was $514 million.

• Capital expenditures for Q2 were $92 million, with full-year projection at $420 million.

Outlook and guidance

• 2024 revenue guidance raised to $9.5–$9.58 billion, with adjusted EPS expected at $8.80–$9.00.

• Capital expenditures projected at $420 million; cash from operations expected at $1.3 billion.

• LifeLabs acquisition not included in 2024 guidance; expected to add $710 million annual revenue and $0.10–$0.15 accretion to adjusted EPS in the first year post-close.

• Operating margin expected to expand for the full year, driven by volume growth and productivity.

• Q3 earnings to be impacted by $0.06–$0.08 due to a global IT outage and Hurricane Beryl.